Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial

Hui-Sheng Chen (), Zi-Ai Zhao, Xin-Yu Shen, Si-Qi Qiu, Yu Cui, Jing Qiu, Wei Li, Hong Zhang, Wen-Huo Chen, Li-Hua Wang, Zhang De-Hui, Ying Chen, Yu-Tong Ma, Zong-En Gao, Shou-Chun Wang, Di Li, Hua Liu and Thanh N. Nguyen
Additional contact information
Hui-Sheng Chen: General Hospital of Northern Theater Command
Zi-Ai Zhao: General Hospital of Northern Theater Command
Xin-Yu Shen: General Hospital of Northern Theater Command
Si-Qi Qiu: General Hospital of Northern Theater Command
Yu Cui: General Hospital of Northern Theater Command
Jing Qiu: General Hospital of Northern Theater Command
Wei Li: General Hospital of Northern Theater Command
Hong Zhang: General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group
Wen-Huo Chen: Zhangzhou Municipal Hospital
Li-Hua Wang: The Second Affiliated Hospital of Harbin Medical University
Zhang De-Hui: Panjin Central Hospital
Ying Chen: Huludao Central Hospital
Yu-Tong Ma: Beipiao Central Hospital
Zong-En Gao: Shengli Oilfield Central Hospital
Shou-Chun Wang: The First Hospital of Jilin University
Di Li: Dalian Municipal Hospital
Hua Liu: The Third People’s Hospital of Chengdu
Thanh N. Nguyen: Neurology, Radiology, Boston Medical Centre

Nature Communications, 2025, vol. 16, issue 1, 1-8

Abstract: Abstract This phase II, randomized, double blinded, multi-center study aims to explore whether intravenous edaravone dexborneol (ED) could improve clinical outcomes in patients with anterior circulation stroke with successful endovascular reperfusion (ClinicalTrials.gov: NCT04667637). Eligible patients were randomly (1:1) assigned into ED, which received intravenous ED (37.5 mg, 2/day, for 12 days) or control group, which received placebo. The primary endpoint was favorable functional outcome (a modified Rankin Scale [mRS] of 0–2 at 90 days). Two hundred patients were enrolled, including 97 in ED group and 103 in control group. The proportion of patients with 90-day mRS (0–2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-57774-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57774-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-57774-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().